The Vikings’ Round 1 Pick Created One Clear Loser

Was it Dillon Thieneman? How about Kenyon Sadiq? Nope — the Minnesota Vikings swerved in Round 1 on Thursday night, […] ...

Venezuela was promised an economic revival. But three months of minimum wage doesn’t add up to a single US dollar

It is payday Friday, and a popular shopping mall located in eastern Caracas is packed. But while the hallways look full and ...

Josh Allen Says Bills Threw Away the Broken Bone That He "Really Wanted" to Keep From Offseason Foot Surgery

As the Buffalo Bills gear up for the voluntary workout phase of the offseason, QB1 Josh Allen has shared an interesting ...

Florida Gators Caleb Banks Gives Key Injury Update Ahead of NFL Draft

On the eve of the NFL Draft, one Florida Gators product has received some meaningful news that could significantly impact his ...
Climate Compass on MSN

California's climate extremes are becoming harder to manage

California has always lived on the edge. Bone-dry summers, lurching rainstorms, scorching valleys, shivering mountain passes.
Hospital Healthcare Europe

Novel compact DT imaging in inflammatory arthritis: a pathway to a first-in-human trial

Prof Karen Knapp discusses the first human trial of a new compact digital tomosynthesis system for inflammatory arthritis.

Where to Go Out in Every World Cup 2026 Host City

Here, WWD Weekend picks some of the best places to stay, eat, shop and explore in each city.

Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.

Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of ...
eLife

Morphine regulates astrocyte transcriptional dynamics in the ventral tegmental area by stimulation of glucocorticoid signaling

Using single-nucleus RNA sequencing, the authors map transcriptional changes in the rat ventral tegmental area following chronic inflammatory pain and acute morphine exposure. Notably, their ...

Regeneron Pharmaceuticals, Inc.: Otarmeni (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for ...

Approval in severe-to-profound and profound OTOF-related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the ...

The Process of Building Patient-Specific Medical Devices with 3D Printing

Discover how medical 3D printing creates patient-specific devices and custom prosthetics. Read our guide to clinical ...